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Abstract
IMPORTANCE The selection criteria for hepatectomy for hepatocellular carcinoma (HCC) is not well
established. The role of noninvasive fibrosismarkers in this setting is unknown in the US population.
OBJECTIVE To evaluate whether aspartate aminotransferase–platelet ratio index (APRI) and fibrosis
4 (Fib4) values are associated with perioperative mortality and overall survival after hepatectomy
for HCC.
DESIGN, SETTING, AND PARTICIPANTS In a multicenter cohort study, Veterans Administration
Corporate DataWarehouse was used to evaluate a retrospective cohort of 475 veterans who
underwent hepatectomy for HCC between January 1, 2000, and December 31, 2012, in Veterans
Administration hospitals. Data analysis occurred between September 30, 2016, and December 30,
2017. Logistic regression, survival analysis, and change in concordance index analysis were
performed to evaluate the association between APRI and Fib4 values andmortality.
EXPOSURES The cohort was stratified based on preoperative APRI and Fib4 values. Analysis was
performed accounting for the validated and established predictors of outcome.
MAINOUTCOMESANDMEASURES Thirty-daymortality, 90-daymortality, and overall survival
were the primary outcomes. An APRI value greater than 1.5 was considered high risk (cirrhosis), and
an Fib4 value greater than 4.0 was considered high risk (advanced fibrosis). Portal hypertension
(diagnosis of ascites or encephalopathy indicates presence of portal hypertension) and Child-
Turcotte-Pugh (CTP) class (A indicates preserved liver function; B, mild to moderate liver
dysfunction) served as 2 other measures of liver function.
RESULTS A total of 475 patients with HCC underwent hepatectomy. The mean (SD) age was 65.6
(9.4) years; Model for End-Stage Liver Disease score, 8.9 (3.1); and body mass index, 28.1 (4.9)
(calculated as weight in kilograms divided by height in meters squared). A total of 361 patients
(76.0%) weremen, 294 (61.9%) were white; 308 (64.8%) were hepatitis C positive, and 346
(72.8%) were categorized as CTP class A. Themost common surgical procedure was partial
lobectomy, with 321 (67.6%) procedures. The APRI value greater than 1.5 vs 1.5 or lower was
associated with increased 30-daymortality (odds ratio [OR], 6.45; 95% CI, 2.80-14.80) and 90-day
mortality (OR, 2.65; 95% CI, 1.35-5.22), as was Fib4 greater than 4.0 vs Fib4 4.0 or lower for 30-day
mortality (OR, 5.41; 95% CI, 2.35-12.50) and 90-daymortality (OR, 2.74; 95% CI, 1.41-5.35). Survival
analysis showed that overall survival was significantly different for APRI greater than 1.5 vs 1.5 or
lower (mean survival time, 3.6 vs 5.4 years; log-rank P < .001) and Fib4 greater than 4.0 vs 4.0 or
lower (mean survival time, 4.1 vs 5.3 years; log rank P = .01). Adjusted Cox proportional hazards
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Abstract (continued)
regression analysis revealed that elevated APRI was significantly associated with worse survival
(hazard ratio [HR], 1.13; 95% CI, 1.03-1.23) but Fib4 values were not (HR, 1.04; 95% CI, 0.99-1.09).
Change in concordance index showed that APRI and Fib4 improved the ability of CTP class and portal
hypertension to predict postoperative mortality.
CONCLUSIONS ANDRELEVANCE Elevated APRI and Fib4 values, which are noninvasivemarkers of
fibrosis, were associated with higher perioperative mortality. The APRI was also associated with
worse overall survival. Use of APRI and Fib4measures improved the ability of establishedmarkers to
predict postoperativemortality. These findings suggest incorporating APRI and Fib4 to the selection
process for hepatectomy for HCC as predictors associated with mortality may be warranted.
JAMA Network Open. 2019;2(1):e187142. doi:10.1001/jamanetworkopen.2018.7142
Introduction
Hepatectomy and liver transplant are themain curative therapies for hepatocellular carcinoma
(HCC).1 Intention-to-treat studies have demonstrated similar overall survival for these therapies.2,3
The selection criteria for HCC resection are not well established.4 The National Comprehensive
Cancer Network guidelines for HCC state that patients with preserved liver function, resectable
disease, who fit United Network for Organ Sharing criteria, could be considered for resection or
transplant, and there remains controversy over which initial strategy is preferable.1 Hepatocellular
carcinoma is currently the fastest rising cause of cancer-related deaths in the United States.5
Although the incidence of HCC tripled between 1975 and 2005, the 5-year survival rate remains
approximately 25%.6 However, this survival rate could be greater than 70%when curative therapy
is applied to early-stage HCC.2,3,7,8
Hepatic fibrosis is associated with an increased risk of postoperative liver failure andmortality
after resection for HCC.9 The noninvasive fibrosis markers (NIFMs) aspartate aminotransferase–
platelet ratio index (APRI) and fibrosis 4 (Fib4) have been shown to accurately predict the presence
of cirrhosis and severe fibrosis when validated with liver biopsy findings.10,11 Studies conducted in
Asian patients with hepatitis B and HCC demonstrated that abnormal levels of NIFMs were
associated with worse postoperative outcomes after hepatectomy.12-14 However, to our knowledge,
the role of these markers in the US population has not been studied. The aim of this study was to
examine the association of APRI and Fib4 with perioperative mortality and overall survival after HCC
resection among US veterans. We hypothesized these NIFMs independently associated with
perioperative mortality and overall survival after hepatectomy for HCC.
Methods
Data Source and Study Cohort
The Veterans Administration (VA) Corporate DataWarehouse database was used. The Corporate
DataWarehouse is a robust and comprehensive database that abstracts clinical information directly
from the computerized patient record system from VA hospitals. Data were accessed, managed, and
analyzed within the VA informatics and computing infrastructure. From January 1, 2000, to
December 31, 2012, all patients with the diagnosis of HCCwere identified using the International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 155.0 (liver cell
carcinoma) and excluding patients with ICD-9-CM code 155.1 (intrahepatic bile duct carcinoma).15 We
included all patients undergoing hepatectomy using the Current Procedural Terminology codes 47120
(partial lobectomy), 47125 (total left lobectomy), 47130 (total right lobectomy), and 47122
(trisegmentectomy). Data abstraction andmanagement started September 30, 2016, and the
analysis was completed on December 30, 2017.
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The study protocol was reviewed and approved by the institutional review board of the
Southern Arizona VA Health Care System, which also waived informed patient consent because this
project was limited to retrospective deidentified data analysis. This study followed the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.16
Patient Demographics and Clinical Factors
Demographic, laboratory, and clinical data were ascertained at the time of resection. Race/ethnicity
information was defined by the participants and was available on the CDW database. The
preoperative laboratory data were obtained from the closest date to surgery. Liver function was
determined using Model for End-Stage Liver Disease (MELD) score (score of 6-9 indicates normal
liver function;10 indicates liver dysfunction) and Child-Turcotte-Pugh (CTP) class (A indicates
preserved liver function; B, mild to moderate liver dysfunction), as previously described.17,18 The
presence of advanced fibrosis and cirrhosis was determined using the NIFMs Fib4 and APRI,
respectively. Based on the studies that validated these NIFMs with liver biopsy andmeta-analysis,
the cutoff value for Fib4 was 4.0 (>4.0 indicates advanced fibrosis) and for APRI, 1.5 (>1.5 indicates
cirrhosis).10,11,19,20 Standard equations were used:
Fib4 = [age (years) × AST level (U/L)] / [platelet count (109) ×ALT level (U/L)], and
APRI = [AST level (U/L) / AST (upper limit of normal)] / platelet count (109) × 100,
where ALT indicates alanine aminotransferase and AST indicates aspartate aminotransferase.
Themain outcomes were defined as perioperative mortality and long-term survival; 30- and
90-daymortality were examined. Long-term survival was evaluated with overall survival comparison
for patients with at least 1-month follow-up.
Statistical Analysis
A 2-tailed, unpaired t test or Mann-Whitney test was used for univariate comparisons of continuous
variables, and Pearson χ2 or Fisher exact test was used for comparison of categorical variables. A
logistic regressionmodel was used to evaluate the association between APRI and Fib4 and
perioperative mortality. Overall survival was calculated from the date of surgery to date of death or
last follow-up. The Kaplan-Meier method was used to plot the survival curves, and comparisons were
performedwith the log-rank test. Cox proportional hazards regression analysis was performed to
evaluate the association between APRI and Fib4 levels with long-term survival. Previously
established predictors of perioperative mortality were included in themultivariate models. To
evaluate the predictive contribution of APRI and Fib4, their association with the concordance index
of the predictive model composed of the established predictors of outcome (CTP and portal
hypertension) were examined as previously described.21 Complete case analysis was used for
missing data.
Statistical comparisons were 2-sided, and P values <.05 were considered significant. The
statistical analysis was conducted using the SAS Enterprise Guide, version 7.1 (SAS Institute Inc).
Results
Patient andOperative Characteristics of theWhole Cohort
A total of 11 497 veterans were diagnosed with HCC between January 1, 2000, and December 31,
2012. Of those, 475 patients (4.1%) underwent liver resection. The clinical characteristics of the
whole cohort are outlined in Table 1. Themean (SD) agewas 65.6 (9.4) years, 361 (76.0%)weremen,
and 294 (61.9%) were white. Hepatitis C, present in 308 patients (64.8%), was the most common
cause of liver disease. Partial lobectomy was performed in 321 patients (67.6%), whereas major
hepatectomywas performed in 154 patients (32.4%). As expected for surgical patients, most had
neither ascites (349 [73.5%]) nor encephalopathy (420 [88.4%]), and CTP class A was themost
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common level (346 [72.8%]). Themean (SD) values were 8.9 (3.1) for MELD, 1.1 (1.3) for APRI, and 3.4
(2.7) for Fib4. Themean follow-up period was 4.7 (3.8) years. The 30- and 90-daymortality rates
were 5.9% and 10.1%, respectively. Themedian overall survival was 3.9 (95% CI, 3.3-4.5) years.
APRI and Fib4AssociationWith PerioperativeMortality and Survival
Logistic regression was performed to examine the association between APRI and Fib4 and the 30-
and 90-day mortality. Compared with patients with APRI values 1.5 or lower, multivariable analysis
revealed that APRI greater than 1.5 was associatedwith worse 30-day (OR, 6.45; 95%CI, 2.80-14.80;
P < .001) and 90-day (OR, 2.65; 95% CI, 1.35-5.22; P = .005) mortality. Likewise, multivariable
analysis showed that, compared with Fib4 levels of 4.0 or lower, Fib4 levels greater than 4.0 were
Table 1. Baseline Clinical Characteristics of 475 PatientsWhoUnderwent Liver Resection
for Hepatocellular Carcinoma
Variable Patients (N = 475)
Age, mean (SD), y 65.6 (9.4)
Sex, No. (%)
Women 8 (1.7)
Men 361 (76.0)
Missing 106 (22.3)
Race, No. (%)
White 294 (61.9)
Other 143 (30.1)
Missing 38 (8.0)
BMI, mean (SD) 28.1 (4.9)
Cirrhosis cause, No. (%)
Non-HCV 167 (35.2)
HCV 308 (64.8)
Hepatectomy type, No. (%)
Major lobectomy (right, left, trisegmentectomy) 154 (32.4)
Partial lobectomy 321 (67.6)
Bilirubin, mean (SD), mg/dL 1.13 (0.4)
Albumin, mean (SD), g/dL 3.97 (3.2)
Missing, No. (%) 22 (4.6)
Creatinine, mean (SD), mg/dL 1.17 (0.48)
INR, mean (SD) 1.11 (0.1)
Ascites, No. (%)
No 349 (73.5)
Yes 126 (26.5)
Encephalopathy, No. (%)
No 420 (88.4)
Yes 55 (11.6)
CTP class, mean (SD), pointsa 5.9 (1.1)
A 346 (72.8)
B 129 (27.2)
MELD score, mean (SD)b 8.9 (3.1)
APRI, mean (SD)c 1.1 (1.3)
Fib4, mean (SD)d 3.4 (2.7)
Follow-up, mean (SD), y 4.7 (3.8)
Mortality, No. (%)
30-Day 28 (5.9)
90-Day 48 (10.1)
Overall survival, y
Mean (SE) 5.1 (0.2)
Median (95% CI) 3.9 (3.3-4.5)
Abbreviations: APRI, aspartate aminotransferase–
platelet ratio index; BMI, bodymass index (calculated
as weight in kilograms divided by height in meters
squared); CTP, Child-Turcotte-Pugh; Fib4, fibrosis 4;
HCV, hepatitis C virus; INR, international normalized
ratio; MELD, Model for End-Stage Liver Disease.
SI conversion units: To convert albumin to grams per
liter, multiply by 10; bilirubin to micromoles per liter,
multiply by 17.104; creatinine to micromoles per liter,
multiply by 88.4.
a CTP A indicates preserved liver function; B, mild to
moderate liver dysfunction.
b MELD score of 6 to 9 indicates normal liver function;
10 or higher indicates liver dysfunction.
c An APRI value greater than 1.5 was considered high
risk (cirrhosis).
d An Fib4 value greater than 4.0 was considered high
risk (advanced fibrosis).
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associated with worse 30-day (OR, 5.41; 95% CI, 2.35-12.50; P < .001) and 90-day (OR, 2.74; 95% CI,
1.41-5.35; P = .003) mortality (Table 2).
Kaplan-Meier survival analysis showed that patients with APRI levels greater than 1.5 had worse
overall survival than patients with APRI levels of 1.5 or lower (mean survival time, 3.6 vs 5.4 years;
log-rank test P < .001) (Figure 1A). The median survival for patients with APRI greater than 1.5 and
APRI 1.5 or less were 2.2 and 4.3 years, respectively. When patients were stratified by Fib4 index, the
overall survival between patients with Fib4 greater than 4.0 was significantly worse than patients
with Fib4 of 4.0 or lower (mean survival, 4.1 vs 5.3 years; log-rank test P = .01) (Figure 1B). The
median survival for patients with Fib4 greater than 4.0 and 4.0 or lower were 2.7 and 4.3 years,
Table 2. Multivariable Logistic Regression Analysis of APRI and Fib4 for 30- and 90-DayMortality
After Hepatectomy for Hepatocellular Carcinoma
Variable Category
30-d Mortality 90-d Mortality
OR (95% CI) P Value OR (95% CI) P Value
APRIa >1.5 6.45 (2.80-14.8) <.001 2.65 (1.35– 5.22) .005
CTP classb B 3.56 (1.37-9.30) .009 3.51 (1.64-7.51) <.001
Portal hypertension Present 7.27 (2.20-24.1) .001 2.74 (1.20-6.28) .01
Fib4c >4.0 5.41 (2.35-12.5) <.001 2.74 (1.41-5.35) .003
CTP classb B 3.53 (1.35-9.17) .009 3.41 (1.58-7.34) .002
Portal hypertension Present 7.18 (2.17-23.7) .001 2.82 (1.22-6.51) .01
Abbreviations: APRI, aspartate aminotransferase–
platelet ratio index; CTP, Child-Turcotte-Pugh; Fib4,
fibrosis 4; OR, odds ratio.
a An APRI value greater than 1.5 was considered high
risk (cirrhosis).
b CTP class B was considered high risk (liver
dysfunction).
c An Fib4 value greater than 4.0 was considered high
risk (advanced fibrosis).
Figure 1. Survival of Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
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respectively. Multivariate Cox proportional hazards regressionmodel analysis was conducted. After
adjusting for CTP and the presence of portal hypertension, APRI was associated with worse overall
survival after hepatectomy for HCC (hazard ratio [HR], 1.13; 95% CI, 1.03-1.23; P = .007). However,
Fib4 was not significantly associated with worse overall survival (HR, 1.04; 95% CI,
0.99-1.09; P = .06).
Change in the Concordance Index andAPRI and Fib4
Concordance index is similar to the area under the receiver operating characteristic (ROC) curve and
measures the probability that, given 2 randompatients, the onewith theworse outcome is predicted
to have a worse outcome.22 To evaluate whether APRI and Fib4 could more accurately predict the
postoperative mortality and overall survival after hepatectomy for HCC, these NIFMSwere added to
themodel containing the established predictors: CTP class and portal hypertension. Table 3 reports
3 regressionmodels for the prediction of 30- and 90-daymortality and overall survival. Each of the 3
models lacks 1 variable, and they are comparedwith the full model containing all variables (reference
model). The predictive accuracy of 30-day mortality was improved by 0.12 (P = .009) when APRI
was incorporated into the establishedmodel (CTP and portal hypertension). Likewise, the ability to
predict 90-daymortality was improved by adding APRI to the establishedmodel by 0.05 (P = .01).
In addition, APRI improved the overall survival prediction by 0.18 (P < .001). Table 3 also
demonstrates the association between Fib4 and the prediction accuracy of perioperative mortality
and overall survival. The improvement of the predictive accuracy of 30- and 90-day mortality by
adding Fib4 to themodel was 0.13 (P = .004) and 0.07 (P = .01), respectively. The long-term survival
predictionwas improved by 0.17 (P = .003). Figure 2 illustrates the ROC curves and their respective
areas under the curve, demonstrating the association between APRI and Fib4 with the predictive
accuracy of 30- and 90-daymortality in patients after hepatectomy for HCC.
Discussion
To our knowledge, this is the largest Western series to examine the role of NIFMs in patients
undergoing hepatectomy for HCC. This study demonstrates the association of APRI and Fib4with the
perioperativemortality and overall survival after hepatectomy for HCC. Using cutoff values described
and validated by previous studies, both APRI and Fib4were independently associatedwith increased
30- and 90-daymortality.10,11,20,23 In addition, APRI was associatedwithworse overall survival, after
adjusting for CTP class and portal hypertension. Child-Turcotte-Pugh classification and portal
hypertension are themost validated and established predictors of outcome after liver resection, and
are broadly used for selection of patients for liver resection for HCC.24 The perioperative mortality
Table 3. Concordance Index Quantifying the Reduction in the Predictive Ability of theModel
Concordance Index Model
30-d Mortality Concordance Index 90-d Mortality Concordance Index Long-term Survival Concordance Index
Decrease (95% CI) P Value Decrease (95% CI) P Value Decrease (95% CI) P Value
APRIa
CTP,b portal hypertension, APRI Full model [reference] NA Full model [reference] NA Full model [reference] NA
CTP, APRI 0.06 (−0.01 to 0.15) .13 0.008 (−0.02 to 0.04) .67 0.11 (0.08 to 0.15) <.001
Portal hypertension, APRI 0.01 (−0.03 to 0.06) .59 0.04 (−0.03 to 0.12) .26 0.08 (0.06 to 0.12) <.001
CTP, portal hypertension 0.12 (0.03 to 0.22) .009 0.05 (0.01 to 0.10) .01 0.18 (0.08 to 0.29) <.001
Fib4c
CTP, portal hypertension, Fib4 Full model [reference] NA Full model [reference] NA Full model [reference] NA
CTP, Fib4 0.03 (−0.03 to 0.10) .35 0.006 (−0.03 to 0.04) .74 0.12 (0.10 to 0.15) <.001
Portal hypertension, Fib4 0.001 (−0.01 to 0.01) .89 0.03 (−0.02 to 0.09) .20 0.10 (0.07 to 0.12) <.001
CTP, portal hypertension 0.13 (0.04 to 0.22) .004 0.07 (0.01 to 0.14) .01 0.17 (0.06 to 0.29) .003
Abbreviations: APRI, aspartate aminotransferase–platelet ratio index; CTP,
Child-Turcotte-Pugh; Fib4, fibrosis 4; NA, not applicable.
a An APRI value greater than 1.5 was considered high risk (cirrhosis).
b CTP class B was considered high risk (liver dysfunction).
c An Fib4 value greater than 4.0 was considered high risk (advanced fibrosis).
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rate within 90 days from surgery for the 475 patients was found to be 10.1%, highlighting the need
for better predictors of postoperative outcomes.
The present study is unique for being what we believe to be the first to demonstrate how APRI
and Fib4 contribute to the ability to predict the perioperative mortality and overall survival beyond
what is achieved by the established predictors. This improvement indicated by APRI and Fib4 was
demonstrated using the concordance index change method.21 The decrease in the concordance
index associated with the addition of APRI or Fib4 to the regressionmodels was statistically
significant for the prediction of 30- and 90-daymortality and overall survival. These findings suggest
that both APRI and Fib4 contribute to the prediction of short- and long-term survival outcomes after
resection of HCC, beyond what is achieved by CTP and portal hypertension.
This study supports the findings of other authors that APRI is independently associated with
poor overall survival after liver resection for HCC.12-14 Hung et al12 and Shen et al13showed that APRI
was associated with worse disease-free and overall survival. Hung et al12 evaluated APRI as a
Figure 2. Sensitivity and Specificity of Aspartate Aminotransferase–Platelet Ratio Index (APRI) and Fibrosis 4 (Fib4) as Indicators ofMortality
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Receiver operating characteristic (ROC) curves with associated areas under the curve. A
and B, APRI and Fib4 improvement of the predictive ability of the models for 30-day
mortality. C and D, APRI and Fib4 improvement of the predictive ability of themodels for
90-daymortality. P values represent the differences in areas under of the curve between
the full model vs themodel without APRI or Fib4 (Child-Turcotte-Pugh [CTP], portal
hypertension). An APRI value greater than 1.5 was considered high risk (cirrhosis), and an
Fib4 value greater than 4.0 was considered high risk (advanced fibrosis).
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surrogate marker of hepatic fibrosis in 76 patients with hepatitis B who underwent hepatectomy for
solitary and small HCC and reported that APRI was a reliable marker for assessing fibrosis and
predicting survival. More recently, Shen et al, examining a cohort of 332 patients, reported that APRI
was associated with worse disease-free and overall survival. The populations of these studies were
predominantly patients with hepatitis B.12,13 A study from Japan, examining a large cohort of patients
with hepatitis C, evaluated the association between APRI and postoperative liver failure. The
investigators demonstrated that APRI was independently associated with an increased risk of
postoperative liver failure.14
To our knowledge, the present study is the first to report the association between APRI and
worse 30- and 90-day postoperativemortality. Furthermore, this appears to be the first report of the
association of Fib4with 30- and 90-daymortality after hepatectomy for HCC. Dong et al23 examined
the association of Fib4 with postoperative complications and intraoperative blood loss in a large
cohort of patients with hepatitis B (n = 350). They demonstrated that Fib4 was independently
associated with adverse postoperative outcomes. Toyoda et al25 evaluated the association of Fib4
and long-term outcome after resection for HCC in a large series of 431 patients. They found that Fib4
was associated with worse disease-free and overall survival. These findings corroborate the results
of our analysis. However, the present analysis differs from these previous studies because it was
based on a large cohort of US veterans. Themain cause of liver disease in these patients was hepatitis
C. Moreover, this study appears to be the first to evaluate the predictive ability of APRI and Fib4 and
their contribution to the established predictors of liver resection outcomes in an organized and
methodologic manner.
For patients with CTP Awithout portal hypertension with resectable HCC, there is still
controversy on which is the preferable initial strategy: liver resection or transplantation. The optimal
selection criteria for these therapies have yet to be established.1 In this analysis, 4.1% of the patients
with HCC underwent liver resection, which is consistent with previous studies on HCC treatment.
Davila et al,26 also using the VAHepatitis C Clinical Case Registry, reported that 4.4% of veterans with
HCC underwent liver resection. Forner et al24 reported that only of 5% to 10% of patients are
candidates for hepatectomy, becausemost centers restrict surgery to patients with good
performance status, a single tumor, preserved liver function, and the absence of portal hypertension
and vascular invasion. Child-Turcotte-Pugh class and portal hypertension are integral parts of the
Barcelona Clinic Liver Cancer Staging System, which is the standard of care for HCCmanagement in
Western countries.24 Therefore, CTP class and portal hypertension were used in our analysis. The
outcomes after hepatectomy for HCC have improved over the past decades, given better surgical
techniques and perioperative care.27,28 Patient selection has played a significant role in reducing
perioperative morbidity andmortality. Therefore, the Barcelona Clinic Liver Cancer Staging System
could be further refined.24
Noninvasive fibrosis markers, such as APRI and Fib4, are attractive markers because they are
easily accessible and determined with routine preoperative laboratory tests. Another unique
characteristic of APRI and Fib4 is that they include the platelet count, which is useful because a low
platelet count has been shown to be associated with increased perioperative morbidity and
mortality.29,30 In addition, APRI and Fib4 are NIFMs that were validated prospectively with liver
biopsy.10,11 Wai et al11 demonstrated that APRI can predict cirrhosis with an area under the ROC curve
of 0.94. Sterling et al10 evaluated the discriminative ability of Fib4 in predicting liver fibrosis,
reporting an area under the ROC curve of 0.756 for severe fibrosis. Therefore, APRI and Fib4 are
good predictors of cirrhosis and fibrosis, respectively. Liver fibrosis and cirrhosis have been described
as markers of impaired hepatic regeneration and increased risk of postoperative liver failure after
hepatectomy.9,31 These findings, associated with the results of the present study, indicate that APRI
and Fib4 are potential predictors of postoperative mortality after hepatectomy for HCC.
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Limitations
This study has several limitations, which are inherent to its observational retrospective design. Some
unmeasured patient characteristics could have changed the results, in particular, the lack of
information on preoperative comorbidities. However, the large number of patients of this cohort and
the analysis accounting for the validated predictors of surgical outcomes helped tominimize possible
selection bias. The VA CDWdatabase constitutes predominately white,male patients. Therefore, the
results of this study may not be generalizable to the overall population. Information on HCC
recurrence and specific cause of death were not available. In addition, information on postoperative
complications was not ascertained. Therefore, it is unknown whether perioperative mortality was
related to liver failure or other causes.
Conclusions
This study suggests that APRI greater than 1.5 and Fib4 greater than 4.0 were independently
associated with increased 30- and 90-daymortality after hepatectomy for HCC. In addition, APRI
was independently associated with worse overall survival. The contribution of APRI and Fib4 to
improve the ability of establishedmarkers in predicting perioperative mortality and overall survival
was supported by valid methods. These findings suggest that incorporating APRI and Fib4 in the
selection process for hepatectomy for HCC as new predictors of mortality may be warranted.
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